0.46
-0.0098(-2.09%)
Currency In USD
| Previous Close | 0.47 |
| Open | 0.48 |
| Day High | 0.49 |
| Day Low | 0.45 |
| 52-Week High | 1.41 |
| 52-Week Low | 0.45 |
| Volume | 1.25M |
| Average Volume | 2.01M |
| Market Cap | 104.64M |
| PE | -1.18 |
| EPS | -0.39 |
| Moving Average 50 Days | 0.68 |
| Moving Average 200 Days | 0.72 |
| Change | -0.01 |
If you invested $1000 in Vaxart, Inc. (VXRT) 10 years ago, it would be worth $17.42 as of March 11, 2025 at a share price of $0.46. Whereas If you bought $1000 worth of Vaxart, Inc. (VXRT) shares 5 years ago, it would be worth $222.22 as of March 11, 2025 at a share price of $0.46.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Vaxart Announces Publication Demonstrating the Immunogenicity and Safety of its First-Generation Oral Pill Norovirus Vaccine Candidate in Elderly Adults
GlobeNewswire Inc.
Mar 05, 2025 9:05 PM GMT
Robust, antigen-specific responses in the nasal cavity following oral administration underscore the efficiency of Vaxart’s oral vaccine platform in generating mucosal antibody responses beyond the site of administrationSOUTH SAN FRANCISCO, Calif., Ma
Vaxart Appoints Seasoned Biotech Executive Kevin Finney to Board of Directors
GlobeNewswire Inc.
Jan 28, 2025 1:00 PM GMT
Mr. Finney brings 35 years of leadership, operations and corporate development experience SOUTH SAN FRANCISCO, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced the appointment of Kevi
Vaxart Highlights Progress of COVID-19, Norovirus and Influenza Programs
GlobeNewswire Inc.
Jan 14, 2025 1:00 PM GMT
COVID-19 Phase 2b study poised to initiate 10,000 participant portion of trial pending U.S. Food and Drug Administration (FDA) review of sentinel cohort 30-day safety data Norovirus program to proceed with Phase 1 study following scientific advisory